A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma (NCT02773030)
Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 As Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma
🩺 Plain-English Summary (8th-Grade Level)
This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220 in combination with DEX and CFZ; and the expansion of the RP2D (Part 2) for CC-220 in combination with DEX for Relapsed Refractory Multiple Myeloma and CC-220 in combination with DEX and BTZ for Newly Diagnosed Multiple Myeloma.
Who can join: Review the eligibility criteria below.
Location: Local Institution - 102 — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (162 Sites)
Showing the first 25 of 162 sites.
- Local Institution - 102 — Scottsdale, Arizona
- Mayo Clinic — Scottsdale, Arizona
- Local Institution - 107 — Little Rock, Arkansas
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Local Institution - 101 — Atlanta, Georgia
- Winship Cancer Institute of Emory University — Atlanta, Georgia
- Local Institution - 120 — Chicago, Illinois
- Robert H Lurie Comprehensive Cancer Center NW Univ — Chicago, Illinois
- Local Institution - 113 — Fairway, Kansas
- University of Kansas Cancer Center — Fairway, Kansas
- Local Institution - 106 — Baltimore, Maryland
- University of Maryland School of Med — Baltimore, Maryland
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Local Institution - 114 — Boston, Massachusetts
- Local Institution - 115 — Boston, Massachusetts
- Massachusetts General Hospital — Boston, Massachusetts
- Dana-Farber/Mass General Brigham Cancer Care, Inc — Boston, Massachusetts
- Local Institution - 110 — Boston, Massachusetts
- Local Institution - 104 — Ann Arbor, Michigan
- University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
- Karmanos Cancer Institute — Detroit, Michigan
- Local Institution - 103 — Detroit, Michigan
- Local Institution - 140 — Grand Island, Nebraska
- Local Institution - 141 — Grand Island, Nebraska
- Local Institution - 137 — Omaha, Nebraska
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma
- Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey
Explore by condition: All Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.